1 / 38

Mycoplasma and Legionella

Mycoplasma and Legionella. Ziad Elnasser, MD, Ph.D. Mycoplasma and Ureaplasma. No cell wall. The smallest of free living organisms. Associated with human disease: Mycoplasma pneumoniae. Mycoplasma hominis. Ureaplasma urealyticum. Microbiology. 0.2 – 0.3 μ pleomorphic, filamentous.

adem
Download Presentation

Mycoplasma and Legionella

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Mycoplasma and Legionella Ziad Elnasser, MD, Ph.D

  2. Mycoplasma and Ureaplasma • No cell wall. • The smallest of free living organisms. • Associated with human disease: • Mycoplasma pneumoniae. • Mycoplasma hominis. • Ureaplasma urealyticum.

  3. Microbiology • 0.2 – 0.3 μ pleomorphic, filamentous. • No cell wall, triple membrane contains sterols from tissue. • No stains, small genome. • Aerobic to facultative anaerobe, grows on Mycoplasma agar, inverted fried egg. • Binds to RBC’s on agar (Hemadsorption).

  4. Mycoplasma pneumoniae • Pneumonia in young, any season. • Atypical pneumonia, scattered patches. • 10% of all Pneumonias. • Droplets, low infectious dose, temperate climates, 5-15y of age. • Sporadic endemic illness in families. • IP 2-15 days, infectivity 60%.

  5. Pathogenesis • Trachea, bronchi, bronchioles and alveoli. • Cytadhesin (P1) binds to oligosaccharides containing sialic acid. • I Ag on surface of RBC’s. • Destroys cillia and causes desquamation. • Shedding 2-8 days before symptoms to 14 weeks after infection.

  6. Immunity • Local and systemic. • CF antibodies, IgA antibodies 2-4 weeks. • Cold agglutinins IgM binds to I Ag on surface of RBC’s in 66% of cases. • Reinfection could occur. • Symptoms related to immune response, more severe in adults. • Raynaud’s phenomena.

  7. Clinical Aspect • Mild tracheobronchitis, fever, cough, headache and malaise. • Less severe pneumonia (walking pneumonia). • X-ray shows patchy pneumonia, lower lobe. • Pleural effusion in 25% • Pharyngitis with fever, sore throat. • Otitis media, myringitis, and pneumonia.

  8. Diagnosis • Clinically overlaps with viral and bacterial. • PMN’s in gram stain, bacteria not seen. • Isolation in special media, incubation for one week or longer. • Serology 4 fold increase in titre. • Cold agglutinins not specific, adenovirus, Epstien barr virus. • Immune assays, DNA hybridization, PCR.

  9. Treatment • Erythromycin, Tetracycline. • Clarthromycin, Azithromycin. • Flouroquinilone.

  10. Legionella • Gram negative bacilli, American legion convention. • Environmental pathogen. • Thin 0.5-0.7μm, filamentous 20μ long. Poor staining with gram but silver impregnation is used (Dieterle). • 3 flagella, motile, non spore former. • Outer membrane LPS but less compared to other g- bacteria.

  11. Growth and Classification • L-cysteine, ferric ions, acidic pH. • 2-5 days needed for growth,ground glass colonies. • Catalase, oxidase, β lactamase. • 14 serogroups, L.bozemanii, L.dumoffii, L.micdadei. • Non infects humans.

  12. Legionellosis • Inhalation, destructive pneumonia. • 1976 American Legion convention. • Other stored sera proved of previous pneumonia caused by Legionella. • Water reservoirs of large buildings. • No person to person transmission. • Not present in healthy people. • Low virulence to humans.

  13. pathogenesis • Necrotizing multifocal pneumonia. • Alveoli and terminal bronchioles. • Inflamatory exudate contains fibrin, PMNs, macrophages, and erythrocytes. • Facultative intracellular pathogen→alveoli →alveolar macrophages→OMP binds C3 facilitates phagocytosis→Macrophage invasion potentiator OMP→cell entry→coiling phagocytosis→apoptosis and pore forming toxin.

  14. Immunity • Virulence because it is intracellular. • CMI is the key. • Inhibition of MHC antigens. • Humoral immunity is less important. • Antibodies only enhancing phagocytosis.

  15. Clinical aspects • Toxic pneumonia, myalgia, headache, fever, dry cough. • Chills, delirium, pleuritic chest pain, vomiting diarrhea. • Patchy infiltrates in chest x-ray. • Hepatic dysfunction. • Mortality is about 15%. • Pontiac fever.

  16. Diagnosis • DFA. • Culture of infected tissues. • Lung aspirates, bronchoalveolar lavage, lung biobsy. • Buffered Charcol Yeast Extract (BCYE). • PCR. • Ag detection.

  17. Treatment • Erythromycin. • Most legionella produces beta lactamases. • Tetracycline, rifampin, newer quinolones. • Azithromycin, clarithromycin. • Prevention:Hyperchlorination of water. • Heating water to more than 70C. • Silver and cupper ionization systems • Mists of water.

  18. Pseudomonas • Gram negative bacillus. • Colonizers and contaminants, apportunistic diseases. • Bacteremia, arthritis, abscesses, wounds, conjunctivitis, UTI.

  19. Ps. aerugenosa • Aerobic motile, g- rod, pale staining. • Colourfull water soluble pigments. • The most resistant to antimicrobial agents. • Simple growth requirements. • 20 – 40 C, Oxidase +, fruity odor. • Pyocyanin, Flourescin. • Lps , pili, polar flagellum, alginate (mannoronic and glucoronic acid) CF pts.

  20. Extracellular products • Exotoxin A ( lecithinase, hemolysis, collagenase). • ADP-ribosylation of EF-2. • Exoenzyme S ADP-ribosylates vimentin acts as adhesin. • Elastases.

  21. Diseases • Environment, throat, stool, > in hospitals. • Leukemia, Cystic fibrosis, and burns. • Humidifiers, inhalators, contact lenses sloutions, medications, disinfectans, sinks. • Food and water no problem. • CF chloride ion transport defect, thick mucus.

  22. pathogenesis • Attachment favored by loss of fibronectin. • Exotoxin A, exotoxin S, and elastin. • Hemorragic destruction of blood vessles. • CS pts cells are less sialated increases receptors for the organism. • Biofilm (glycocalyx), alginate over produced. • Interfers with antibiotics and Immune mechanisms. • CMI deficient patients.

  23. Clinical aspects • Apportunists. • pnemonia and in CF is chronic. • Otitis externa, swimmers ear, in DM. • Ecthyma gangrenosum. • Diagnosis is simple.

  24. Treatment • Most resistant to penicillin, ampicillin, cephalothin, tetracyclin, streptomycin, chloramphenicol, sulfonamide. • New aminoglycosides. • Third and fourth generation cephalosporins. • Carbapenems and flouroquinolones. • CF aerosolized tobramycin. • Vaccines tried in CF some improvement. • Burkholderia, Acinetobacter, aeromonas and pleisomonas.

More Related